IFF
60
-3
PEP
50
-4
KLAC
56
-3
CNX
76
5
UNP
48
-2
TRV
64
-3
HUM
30
3
ED
53
-5
GOOG
63
2
ETN
73
-2
PSX
42
3
SLG
66
4
MSFT
54
-3
FLS
46
-7
PM
52
-4
TGNA
51
3
TJX
50
2
ES
55
-5
SPG
53
-2
D
55
-6
IFF
60
-3
PEP
50
-4
KLAC
56
-3
CNX
76
5
UNP
48
-2
TRV
64
-3
HUM
30
3
ED
53
-5
GOOG
63
2
ETN
73
-2
PSX
42
3
SLG
66
4
MSFT
54
-3
FLS
46
-7
PM
52
-4
TGNA
51
3
TJX
50
2
ES
55
-5
SPG
53
-2
D
55
-6
Financhill
Back

Zevra Therapeutics 10K Form

Buy
52

ZVRA
Zevra Therapeutics

Last Price:
8.00
Seasonality Move:
-17.07%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ZVRA News And Ratings

See the #1 stock for the next 7 days that we like better than ZVRA

ZVRA Financial Statistics

Sales & Book Value

Annual Sales: $27.46M
Cash Flow: $-19.11M
Price / Cash Flow: 0
Annual Sales: $0.77
Price / Book: 12.69

Profitability

EPS (TTM): -1.68000
Net Income (TTM): $-65.75M
Gross Margin: $24.52M
Return on Equity: -117.77%
Return on Assets: -46.14%

Zevra Therapeutics Earnings Forecast

Key Zevra Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for ZVRA is 89.28%.
  • The Selling, General & Administrative Expenses for ZVRA have been equal to 124.96% of Gross Profit Margin.
  • The Research & Development expenses have been 144.95% of Revenue.
  • The Interest Expense is -3.26% of Operating Income.
  • The Net Earning history of ZVRA is -167.69% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Zevra Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ZVRA
Website: zevra.com

Debt

Debt-to-Equity Ratio: 1.8
Current Ratio: 2
Quick Ratio: 1.91

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ZVRA Technical Analysis vs Fundamental Analysis

Buy
52
Zevra Therapeutics (ZVRA) is a Buy

Is Zevra Therapeutics a Buy or a Sell?